Unlock stock picks and a broker-level newsfeed that powers Wall Street.
IOB - Delayed Quote DKK

Coloplast A/S (0QBO.IL)

Compare
697.30
-1.80
(-0.26%)
At close: April 4 at 5:04:31 PM GMT+1
Loading Chart for 0QBO.IL
  • Previous Close 699.10
  • Open 715.60
  • Bid 672.00 x --
  • Ask 711.60 x --
  • Day's Range 690.80 - 722.00
  • 52 Week Range 690.80 - 959.00
  • Volume 75,195
  • Avg. Volume 29,376
  • Market Cap (intraday) 161.229B
  • Beta (5Y Monthly) 0.26
  • PE Ratio (TTM) 30.99
  • EPS (TTM) 22.50
  • Earnings Date May 6, 2025
  • Forward Dividend & Yield 20.00 (2.76%)
  • Ex-Dividend Date May 15, 2023
  • 1y Target Est --

Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

www.coloplast.com

14,700

Full Time Employees

September 30

Fiscal Year Ends

Recent News: 0QBO.IL

View More

Performance Overview: 0QBO.IL

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is OMX Copenhagen 25 Index (^OMXC25) .

YTD Return

0QBO.IL
11.90%
OMX Copenhagen 25 Index (^OMXC25)
4.06%

1-Year Return

0QBO.IL
23.75%
OMX Copenhagen 25 Index (^OMXC25)
11.75%

3-Year Return

0QBO.IL
28.95%
OMX Copenhagen 25 Index (^OMXC25)
4.72%

5-Year Return

0QBO.IL
26.18%
OMX Copenhagen 25 Index (^OMXC25)
50.96%

Compare To: 0QBO.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0QBO.IL

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    156.27B

  • Enterprise Value

    180.12B

  • Trailing P/E

    32.13

  • Forward P/E

    26.74

  • PEG Ratio (5yr expected)

    2.36

  • Price/Sales (ttm)

    5.72

  • Price/Book (mrq)

    10.16

  • Enterprise Value/Revenue

    6.56

  • Enterprise Value/EBITDA

    20.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.66%

  • Return on Assets (ttm)

    12.40%

  • Return on Equity (ttm)

    69.51%

  • Revenue (ttm)

    24.33B

  • Net Income Avi to Common (ttm)

    4.78B

  • Diluted EPS (ttm)

    22.50

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    855M

  • Total Debt/Equity (mrq)

    340.76%

  • Levered Free Cash Flow (ttm)

    2.74B

Research Analysis: 0QBO.IL

View More

Company Insights: 0QBO.IL

Research Reports: 0QBO.IL

View More

People Also Watch